Brief: Merus Announces FDA Approval Of Bizengri® (Zenocutuzumab-Zbco)

Merus NV

04/12/2024 21:56

Dec 4 (Reuters) - Merus NV  2GH.F :
    * MERUS ANNOUNCES FDA APPROVAL OF BIZENGRI®
(ZENOCUTUZUMAB-ZBCO)
FOR NRG1+ PANCREATIC ADENOCARCINOMA AND NRG1+ NON–SMALL CELL
LUNG CANCER (NSCLC) BASED ON SAFETY AND EFFICACY DATA FROM THE
ENRGY STUDY
    * MERUS NV - BIZENGRI HAS BOXED WARNING FOR EMBRYO-FETAL
TOXICITY
AND OTHER RISKS

Source text:  ID:nGNX9ZTm6f 
Further company coverage:  2GH.F 

 ((Reuters.Briefs@thomsonreuters.com;))